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A B S T R A C T
Background
Cough both protects and clears the airway. Cough has three phases: breathing in (inspiration), closure of the glottis, and a forced
expiratory effort. Chronic cough has a negative, far-reaching impact on quality of life. Few effective medical treatments for individuals
with unexplained (idiopathic/refractory) chronic cough (UCC) are known. For this group, current guidelines advocate the use of
gabapentin. Speech and language therapy (SLT) has been considered as a non-pharmacological option for managing UCC without the
risks and side effects associated with pharmacological agents, and this review considers the evidence from randomised controlled trials
(RCTs) evaluating the effectiveness of SLT in this context.
Objectives
To evaluate the effectiveness of speech and language therapy for treatment of people with unexplained (idiopathic/refractory) chronic
cough.
Search methods
We searched the Cochrane Airways Trials Register, CENTRAL, MEDLINE, Embase, CINAHL, trials registries, and reference lists of
included studies. Our most recent search was 8 February 2019.
Selection criteria
We included RCTs in which participants had a diagnosis of UCC having undergone a full diagnostic workup to exclude an underlying
cause, as per published guidelines or local protocols, and where the intervention included speech and language therapy techniques for
UCC.
Data collection and analysis
Two review authors independently screened the titles and abstracts of 94 records. Two clinical trials, represented in 10 study reports, met
our predefined inclusion criteria. Two review authors independently assessed risk of bias for each study and extracted outcome data. We
analysed dichotomous data as odds ratios (ORs), and continuous data as mean differences (MDs) or geometric mean differences. We
used standard methods recommended by Cochrane. Our primary outcomes were health-related quality of life (HRQoL) and serious
adverse events (SAEs).
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Main results
We found two studies involving 162 adults that met our inclusion criteria. Neither of the two studies included children. The duration of
treatment and length of sessions varied between studies from four sessions delivered weekly, to four sessions over two months. Similarly,
length of sessions varied slightly from one 60-minute session and three 45-minute sessions to four 30-minute sessions. The control
interventions were healthy lifestyle advice in both studies.
One study contributed HRQoL data, using the Leicester Cough Questionnaire (LCQ), and we judged the quality of the evidence to
be low using the GRADE approach. Data were reported as between-group difference from baseline to four weeks (MD 1.53, 95%
confidence interval (CI) 0.21 to 2.85; participants = 71), revealing a statistically significant benefit for people receiving a physiotherapy
and speech and language therapy intervention (PSALTI) versus control. However, the difference between PSALTI and control was not
observed between week four and three months. The same study provided information on SAEs, and there were no SAEs in either the
PSALTI or control arms. Using the GRADE approach we judged the quality of evidence for this outcome to be low.
Data were also available for our prespecified secondary outcomes. In each case data were provided by only one study, therefore there were
no opportunities for aggregation; we judged the quality of this evidence to be low for each outcome. A significant difference favouring
therapy was demonstrated for: objective cough counts (ratio for mean coughs per hour on treatment was 59% (95% CI 37% to 95%)
relative to control; participants = 71); symptom score (MD 9.80, 95% CI 4.50 to 15.10; participants = 87); and clinical improvement
as defined by trialists (OR 48.13, 95% CI 13.53 to 171.25; participants = 87). There was no significant difference between therapy
and control regarding subjective measures of cough (MD on visual analogue scale of cough severity: −9.72, 95% CI −20.80 to 1.36;
participants = 71) and cough reflex sensitivity (capsaicin concentration to induce five coughs: 1.11 (95% CI 0.80 to 1.54; participants
= 49) times higher on treatment than on control). One study reported data on adverse events, and there were no adverse events reported
in either the therapy or control arms of the study.
Authors’ conclusions
The paucity of data in this review highlights the need for more controlled trial data examining the efficacy of SLT interventions in the
management of UCC. Although a large number of studies were found in the initial search as per protocol, we could include only two
studies in the review. In addition, this review highlights that endpoints vary between published studies.
The improvements in HRQoL (LCQ) and reduction in 24-hour cough frequency seen with the PSALTI intervention were statistically
significant but short-lived, with the between-group difference lasting up to four weeks only. Further studies are required to replicate
these findings and to investigate the effects of SLT interventions over time. It is clear that SLT interventions vary between studies.
Further research is needed to understand which aspects of SLT interventions are most effective in reducing cough (both objective cough
frequency and subjective measures of cough) and improving HRQoL. We consider these endpoints to be clinically important. It is also
important for future studies to report information on adverse events.
Because of the paucity of data, we can draw no robust conclusions regarding the efficacy of SLT interventions for improving outcomes
in unexplained chronic cough. Our review identifies the need for further high-quality research, with comparable endpoints to inform
robust conclusions.
P L A I N L A N G U A G E S U M M A R Y
Speech and language therapy for chronic cough
Background to the question
People normally cough to protect and clear the airways. For example, when we have a chest infection, we cough to eject bacteria. Or
when we breathe in dust, we cough to eject the dust. Some people have chronic, or long-term cough, due to a disease such as asthma,
chronic obstructive pulmonary disease (COPD), or gastro-oesophageal reflux disease. However, some people have chronic cough for
no obvious reason. This is known as unexplained (idiopathic/refractory) chronic cough (UCC). Coughing over months and years is
unpleasant, causing a reduction in quality of life.
Current guidelines recommend the use of gabapentin (a drug usually used to control seizures and reduce nerve pain) to try to stop
people with UCC from coughing. However, this drug has side effects including drowsiness.
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Speech and language therapy (SLT) has been suggested as a non-drug-based option for managing UCC. Speech and language therapy
would avoid the risks and side effects of medication.
Speech and language therapy aims to teach people to control their cough. The person is taught methods to help them suppress the urge
to cough. Education is given with the intention to help people understand how the technique works and hopefully get them to stick
with it. People also receive vocal hygiene information. Vocal hygiene involves techniques to reduce the trigger to cough. For example,
vocal hygiene may involve helping someone breathe through their nose rather than their mouth and avoiding drinking alcohol and
caffeine, which can worsen cough. They may also be given psychoeducational counselling to help them learn they have the means to
control their cough.
This review assessed the latest evidence regarding the effectiveness of SLT in the management of UCC.
Study characteristics
We found two relevant studies to include in the review. Both studies were randomised controlled trials (a type of study in which
participants are assigned to one of two or more treatment groups using a random method) in which participants had a diagnosis of
UCC. Participants received either an intervention including SLT techniques or ’healthy lifestyle advice’ as a control group. We chose
to use health-related quality of life and serious adverse events to judge whether SLT is a useful intervention.
Main results
Only one of the studies comparing SLT to usual care reported data about quality of life (using a questionnaire). After four weeks,
participants in the study who were receiving the SLT treatment, physiotherapy and speech and language therapy intervention (PSALTI),
had on average an improvement in their quality of life compared to people in the control group. However, this benefit compared to
control was short-lived and disappeared after four weeks. This means that although the treatment appeared to work in the shorter term,
it may not improve quality of life in the longer term compared to usual care.
We also looked for information about side effects or harms of the treatment. The same study reported that no one experienced serious
side effects or harms during the study.
Other ways of measuring the impact of SLT were also considered, and in each case relevant data were only provided by one study.
An improvement in objective cough counts (using a cough monitor), symptoms (using symptom scores), and clinical improvement
was shown with SLT compared to controls. The included trials reported no difference for other secondary outcomes such as subjective
measures of cough or cough reflex sensitivity (measured in the laboratory using airway irritants).
Quality of the evidence
The small number of high-quality, relevant studies found in this review means that we cannot be sure of the overall benefits of SLT in
the management of UCC. Improvements in health-related quality of life were associated with the PSALTI intervention over a short
period in one study, but further research is required to replicate this finding. Overall, more controlled trials are required to fully examine
the potential of SLT for the management of UCC.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Speech and language therapy compared with control for chronic cough
Patient or population: part icipants with chronic cough
Settings: hospital
Intervention: speech and language therapy
Comparison: Healthy lif estyle advice
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1A point was deducted to ref lect the study quest ion precluding the opportunity to double-blind.
2A point was deducted to ref lect imprecision (data f rom a single study with modest sample size).











































































































B A C K G R O U N D
Description of the condition
Cough is a reflex action to clear the airways of mucus and irritants
such as smoke. Cough is a sequence comprising an inspiratory,
glottic (vocal fold) closure, then a forced expiratory effort initially
against the closed glottis (Fontana 2008). The duration of cough
can be acute (less than three weeks), subacute (between three and
eight weeks), or chronic (longer than eight weeks) (Irwin 2006).
Details regarding the theory and treatment of cough can be found
in several different clinical fields, including otolaryngology, respi-
ratory medicine, speech and language therapy, respiratory physi-
ology, and physiotherapy (Vertigan 2016a).
Unexplained (idiopathic/refractory) chronic cough (UCC) is a
cough that persists after common causes have been evaluated and
ruled out and medical management options have not offered any
convincing relief from symptoms. This condition is a diagnosis of
exclusion following a careful diagnostic workup to exclude other
causes of cough such as underlying lung/airways disease, gastro-
oesophageal reflux, drugs (such as angiotensin-converting enzyme
inhibitors (ACEis)), and rhinosinusitis (Gibson 2016a; Morice
2006; Morice 2007; Morice 2007a; Vertigan 2016a).
Evidence suggests that UCC may be caused by neural hyper-re-
sponsiveness. The observation that lower concentrations of tussive
agents are required to induce cough in participants with UCC
compared with healthy controls illustrates an increase in sensitivity
of the cough reflex (Prudon 2005). Symptomatically, patients with
this condition describe an ’irritation’ or ’tickle’ within the throat
and a heightened urge or need to cough (Hilton 2015). Functional
magnetic resonance imaging (fMRI) studies have demonstrated a
clear role of the central nervous system in the sensation or urge to
cough (Farrell 2014; Leech 2013; Mazzone 2007; Mazzone 2011),
as well as a failure of descending inhibition of cough (Ando 2016).
It is known that vagal afferent bronchopulmonary C-fibres as well
as A-delta fibres are important in cough (Belvisi 2003; Canning
2014). Novel drugs targeting C-fibre receptors have been recently
trialed in humans. An oral transient receptor potential vanilloid
subtype 1 (TRPV1) antagonist had no effect on cough frequency
but did reduce cough reflex sensitivity in participants with UCC
(Khalid 2014). Another, more potent, TRPV1 antagonist showed
similar results in a more recent randomised controlled trial (RCT)
(Belvisi 2017). In contrast, targeting the P2X3 receptor demon-
strated a 75% reduction in daytime cough frequency in partici-
pants with UCC using a novel P2X3 antagonist (Abdulqawi 2015),
supporting the hypothesis of a neural mechanism in UCC.
Furthermore, an overlap has been postulated between chronic
cough and other laryngeal dysfunction presentations, such as in-
ducible laryngeal obstruction (ILO), extra-thoracic responsive-
ness, globus pharyngeus, hyperfunctional muscle tension, mus-
cle tension dysphonia, voice disorders, and dysphagia symptoms
(Altman 2002; Irwin 2010; Morrison 1999; Ryan 2009; Song
2014; Vertigan 2006; Vertigan 2012; Vertigan 2013; Vertigan
2016a; Vertigan 2019). Inducible laryngeal obstruction, previ-
ously known as vocal cord dysfunction (VCD) or paradoxical vo-
cal form movement (PVFM), is an “inappropriate, transient, re-
versible narrowing of the larynx in response to external triggers”
(Halvorsen 2017), leading to symptoms of shortness of breath,
dysphonia, and cough (Vertigan 2016a). Symptoms of ILO are
localised to the larynx (Benninger 2011). It has been suggested
that these symptoms may represent different manifestations of
an underlying hypersensitive and hyper-responsive upper airway
(Morrison 1999; Vertigan 2007a; Vertigan 2010; Vertigan 2016a).
Description of the intervention
Speech and language therapy (SLT) offers a non-pharmacologi-
cal intervention for people with UCC who may have exhausted
medical treatment for their condition, or who wish to pursue a
non-pharmacological treatment option (Haines 2015; Ryan 2010;
Ryan 2014; Vertigan 2006; Vertigan 2016a). Speech and language
therapy has been incorporated into the Treatment of unexplained
chronic cough: CHEST guideline and expert panel report (Gibson
2016a), which details treatment of UCC, and the Australian cough
guidelines summary statement (Gibson 2010). The goal of SLT
is to reduce laryngeal irritation that can trigger an individual’s
urge to cough, and to increase voluntary control of cough by in-
terrupting or preventing coughing episodes, as well as to address
symptoms associated with dysphonia and ILO (Vertigan 2016a;
Vertigan 2019).
Speech and language therapists are appropriately trained to man-
age chronic cough via a combination of detailed knowledge of
anatomy and physiology of the upper airway, experience in edu-
cation and training on respiratory physiology and clinical voice
disorders, and knowledge of interventions to modify laryngeal be-
haviour (Altman 2000; Stemple 2009). As there is a hypothesised
and clinically recognised overlap between cough and other upper
airway and laryngeal disorders, such as ILO, globus pharyngeus,
muscle tension dysphonia, and dysphagic symptoms, SLT profes-
sionals have the skills required to identify, assess, and manage these
overlapping conditions effectively by applying techniques tradi-
tionally used to treat muscle tension voice disorders (Blager 1998;
Blager 2000; Carney 1997; Chhetri 2014; Dunn 2015; Estill
2009; Estill 2009a; Ryan 2010; TitzeI 2006; Vertigan 2007a).
Speech and language therapy assessment can also investigate pa-
tient-reported symptoms of dysphagia to identify clinical signs of
aspiration that may warrant further investigation (Vertigan 2013;
Vertigan 2016a; Irwin 2010).
Given the overlap between chronic cough and other upper airway
and laryngeal disorders, videolaryngoscopy may assist differential
diagnosis and consequent targeted therapy (Forrest 2012; Vertigan
2016a). Furthermore, the trained SLT professional can provide
biovisual feedback with videolaryngoscopy. This has been found
to be useful for assisting patients in applying techniques and in
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helping to monitor response to SLT in other related conditions
such as clinical voice disorders and ILO (Balkissoon 2012; Belafsky
2001; Christopher 2010; Hull 2016; Olin 2017).
The urge to cough and indicators suggestive of ILO can be evalu-
ated through the use of scales (e.g. Davenport 2002) (Ryan 2014;
Traister 2014). Hyperfunction in the larynx during voicing can
signify laryngeal dysfunction and can serve as a contributory fac-
tor to cough reflex sensitivity. Voicing is often cited as a trigger for
coughing episodes. A clinical voice assessment can use recognised
descriptive rating scales of perceptual voice characteristics, such as
rough, breathy, and strained vocal qualities (Hirano 1981; Omori
2011; Ryan 2014; Vertigan 2007a).
The SLT professional can also assess voice production instrumen-
tally (Ryan 2010; Zelcer 2002), for example by using an acous-
tic voice analysis programme or visualising the larynx via video-
laryngoscopy during voice use according to a recognised protocol
(RCSLT 2008). Manual assessment of tension in the extrinsic la-
ryngeal musculature is a useful tool for assessing hyperfunction,
which can be detected in muscle tension voice disorders (Rubin
2000; Vertigan 2016a).
Vertigan 2012 and Vertigan 2016a outlined a multidimensional
SLT intervention for chronic cough management consisting of the
following elements.
Education
Education focusses on encouraging adherence, with the aim of
acceptance that patients can control their cough and take steps at
the first sign of the urge to cough to implement cough suppression
strategies such as cough suppression swallow, controlled breathing,
relaxed throat breathing, and ILO release breathing (Vertigan
2016). Patients are provided with information on the importance
of sustained application of cough suppression techniques (Vertigan
2012), as well as reassurance that their cough is not necessary or
beneficial to them.
Education is provided on the perpetuating nature of the cough, and
how this can potentially lead to an increased laryngeal sensitivity,
laryngeal trauma, and laryngeal tension. Specific goals for therapy
are planned with the patient. The ultimate goal of SLT is for the
patient to control the cough, even in the presence of the sensation
or urge to cough.
Symptom control techniques
The aim of symptom control strategies is to enable the patient
to prevent, stop, or interrupt the cough despite having the trig-
gering sensation or urge. The patient is taught to substitute the
cough with a competing response (e.g. distraction, cough suppres-
sion swallow, relaxed throat breathing, a sip of fluids, laryngeal
deconstriction) (Estill 2009; Vertigan 2007a). Laryngeal control
techniques for any coexisting inducible laryngeal obstruction can
also be included in the therapy intervention (Blager 2000; Boone
1993; Chhetri 2014; Kotby 1993).
A hierarchy for applying control techniques can be devised with
the patient; this can include graded exposure to desensitise the
patient to particular triggers, and facilitate automaticity of tech-
niques when symptomatic (Vertigan 2016).
Reducing laryngeal irritation via vocal hygiene
Vocal hygiene advice is routinely used in the SLT approach to
clinical voice disorders (Blager 1988), and it may be beneficial in
the treatment of UCC (Vertigan 2012). Vocal hygiene consists of
advice on reducing irritation and trauma to the upper airway, for
example the potential harmful effects of smoking, mouth breath-
ing, caffeine, and alcohol on laryngeal mucosa. Easy voicing and
adequate hydration are emphasised and demonstrated to reduce
the risk of phonotrauma (Boone 1993; Kotby 1993; Murry 2004;
Solomon 2014; Vertigan 2007a). Information on diet and be-
havioural management of gastro-oesophageal and laryngopharyn-
geal reflux is provided (Koufman 2011; Vertigan 2019).
Psychoeducational counselling
The therapist can assess readiness to engage in SLT, as this may
impact the efficacy of therapy (Prochaska 1982). Acceptance that
the patient can control the cough (internal locus of control), self-
efficacy (Bandura 1986), and the effort required of the patient
are made explicit, with emphasis on treatment being ’hard work’.
Realistic, targeted goal setting helps the therapist to direct inter-
ventions and monitor progress (Murry 2004; Ryan 2010; Vertigan
2012).
Overall goals of speech and language therapy interventions can be
summarised as follows (Gibson 2015a).
1. Reduce the sensitivity of the cough reflex.
2. Encourage improvement in voluntary control of cough.
3. Reduce irritation of the larynx.
How the intervention might work
Speech and language therapy interventions aim to improve a per-
son’s control over cough and symptoms associated with any over-
lapping dysphonia and ILO (Vertigan 2016a), but the mech-
anism(s) by which multimodal SLT interventions may reduce
cough severity and frequency, leading to improvement in health-
related quality of life, is poorly understood. However, it is pos-
tulated that SLT management of UCC can help break the cycle
of reciprocal irritation of cough receptors by increasing voluntary
cognitive control of the urge to cough, reducing cough reflex sen-
sitivity, reducing laryngeal irritation and laryngeal muscle tension,
and also treating any coexisting paradoxical vocal fold movement
(Ryan 2010; Vertigan 2016; Vertigan 2019).
Speech and language therapy interventions have been shown
to reduce cough sensitivity in participants with UCC (Ryan
2009; Smith 2005; Vertigan 2006; Vertigan 2016). However,
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a multicentre RCT demonstrated no differences between in-
tervention and control groups with capsaicin cough challenge
(Chamberlain Mitchell 2017). The psychoeducational and con-
trol strategies component may support subjective improvement
in chronic cough management techniques and may reduce upper
airway muscle tension (Canning 2006; Gibson 2009). Improved
laryngeal hygiene attained via hydration and education on reduc-
tion of laryngeal injury may support lower phonation threshold
pressure, thereby reducing stimulation of cough receptors (Casper
2003; Solomon 2014).
Vertigan 2019 details that the overall mechanism for improve-
ment in cough symptoms following multimodal SLT intervention
is unknown. However, it could represent both a central action in
improved function of the neural cough suppression networks and
laryngeal control, and a peripheral action demonstrated by a re-
duction in laryngeal hypersensitivity.
Why it is important to do this review
Cough is one of the most common reasons why patients seek
medical advice (Morice 2006). The reported prevalence of chronic
cough in the population varies in the most recent studies from 4%,
Colak 2017, to 9.6% (Song 2015). Cough presents a considerable
financial burden, with acute cough costing approximately GBP
979 million in the UK, including GBP 875 million in loss of
productivity and GBP 104 million in healthcare costs (Morice
2006). The cost of chronic cough to the economy remains unclear.
The impact of chronic cough on quality of life is far reaching
and can include negative physical, psychological, and social conse-
quences (Decalmer 2007; French 1998; McGarvey 2013). Patient-
reported impact has been reported to be comparable to the impact
of stroke or Parkinson’s disease (Song 2013). Reported psycholog-
ical and physical morbidities include vomiting, social embarrass-
ment, headaches, low mood, and sleep disturbance (Chamberlain
2013). Urinary incontinence associated with chronic cough is a
particularly distressing symptom (Hrisanfow 2013).
Few effective medical treatments for individuals with UCC are
known. Current guidelines advocate the use of gabapentin (Gibson
2016a), following improvements in quality of life reported in an
RCT of gabapentin in UCC (Ryan 2012). One study demon-
strated a reduction in subjective cough scores in response to slow-
release morphine sulphate (Morice 2007a). Another study exam-
ined amitriptyline in participants with postviral vagal neuropathy
and cough, but guidelines do not currently recommend this treat-
ment (Jeyakumar 2006).
Speech and language therapy has been advocated as an attractive
non-pharmacological option for managing UCC without the risks
and side effects associated with pharmacological agents and is ad-
vocated in guidelines (Gibson 2016a). Speech and language ther-
apy was the focus of this review.
O B J E C T I V E S
To evaluate the effectiveness of speech and language therapy
for treatment of people with unexplained (idiopathic/refractory)
chronic cough.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs). We included
studies reported in full text, those published as an abstract only, and
unpublished data. We planned to include cluster trials and first-
period data from cross-over trials if these were available, however
all of the included studies were of conventional parallel-group
design.
Types of participants
We included participants with a diagnosis of unexplained chronic
(idiopathic/refractory) cough (UCC) who had undergone a full
diagnostic workup to exclude an underlying cause, as per published
guidelines or local protocols. Had we identified eligible studies in
children (17 years of age and younger), we would have analysed
them separately from adult studies, however all of the included
studies focused on adult participants.
Types of interventions
We included studies that used recognised speech and language
therapy (SLT) techniques for UCC, such as the multidimensional
SLT intervention described in the Background section (educa-
tion, symptom control or vocal hygiene, psychoeducational coun-
selling) and/or other recognised SLT laryngeal control techniques
as defined by trialists.
We planned to include other co-interventions, provided they were
not part of the randomised treatment.
We included studies comparing SLT and usual care versus usual
care, such as reassurance, lifestyle advice, and background medi-
cations. We also planned to include studies comparing SLT versus
an ’active’ control such as non-prescribed/over-the-counter cough
products (e.g. lozenges). We included trials that delivered a num-
ber of sessions and planned to investigate in subgroup analyses the
number of sessions provided wherever possible (Ryan 2010).
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Types of outcome measures
Primary outcomes
1. Health-related quality of life (assessed via a validated
measure)
2. Serious adverse events
Secondary outcomes
1. Objective cough counts (e.g. using the Leicester Cough
Monitor (LCM))
2. Symptoms (preferentially assessed on validated symptom
scales)
3. Clinical improvement (as defined by trialists)
4. Subjective measures of cough (e.g. visual analogue scale
(VAS)/numerical cough scale score)
5. Cough reflex sensitivity (as measured by cough challenge)
6. Adverse events/side effects
Reporting in the study of one or more of the outcomes listed was
not an inclusion criterion for this review.
Search methods for identification of studies
Electronic searches
The Cochrane Airways Group Information Specialist conducted
systematic searches in the following sources:
1. Cochrane Airways Trials Register via the Cochrane Register
of Studies (CRS-Web), searched on 8 February 2019;
2. Cochrane Central Register of Controlled Trials
(CENTRAL), via the Cochrane Register of Studies (CRS-Web),
searched on 8 February 2019;
3. MEDLINE Ovid SP from 1946 to 8 February 2019;
4. Embase Ovid SP from 1974 to 8 February 2019;
5. CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature) from 1937 to 8 February 2019;
6. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov/). searched on 8
February 2019;
7. World Health Organization International Clinical Trials
Registry Platform ( WHO ICTRP) ( apps.who.int/trialsearch/)
searched on 8 February 2019
Search strategies are provided in Appendix 1.
We searched all sources from inception to the present, with no
restriction on language of publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We searched for errata or retrac-
tions from included studies published in full text on PubMed (
www.ncbi.nlm.nih.gov/pubmed) and reported within the review
the date this was done (February 2019).
Data collection and analysis
Selection of studies
Two review authors (CS and PM) independently screened the ti-
tles and abstracts of studies identified by the search and coded
them as ’retrieve’ (eligible or potentially eligible/unclear) or ’do
not retrieve’. We retrieved the full-text study reports of all poten-
tially eligible studies, and two review authors (CS and PM) in-
dependently screened them for inclusion, while recording reasons
for exclusion of ineligible studies. We planned to resolve any dis-
agreements through discussion, consulting a third person/review
author (AV) if necessary, however this was not required. We iden-
tified and excluded duplicates and collated multiple reports of the
same study so that each study, rather than each report, was the
unit of interest in the review. We recorded the selection process in
sufficient detail to complete a PRISMA flow diagram and ’Char-
acteristics of excluded studies’ tables (Moher 2009).
Data extraction and management
We used a data collection form that had been piloted on at least
one study in the review to record study characteristics and outcome
data. Two review authors (SJM and JM) extracted the following
study characteristics from the included studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals, and dates of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for studies and notable conflicts of interest
of trial authors.
Two review authors (SJM and JM) independently extracted out-
come data from the included studies. We noted in the ’Charac-
teristics of included studies’ table if outcome data were not re-
ported in a manner precluding them from being entered into the
Review Manager 5 file (RevMan 2014). We planned to resolve
any disagreements by consensus, consulting a third person/review
author (PM) if necessary, however this was not required. One re-
view author (SJM) transferred data into the Review Manager 5
file (RevMan 2014). A second review author (CS) double-checked
that study characteristics and data had been entered correctly by
comparing the data presented in the systematic review against that
in the study reports.
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Assessment of risk of bias in included studies
Two review authors independently (SJM and JM) assessed risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We planned to resolve any disagreements by discussion, consult-
ing another review author (PM) if necessary, however this was not
required. We assessed risk of bias according to the following do-
mains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We judged each potential source of bias as high, low, or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised
’Risk of bias’ judgements across different studies for each of the
domains listed. We considered blinding separately for different key
outcomes when necessary (e.g. for unblinded outcome assessment,
risk of bias for all-cause mortality may be very different than for
use of a patient-reported pain scale). When information on risk of
bias related to unpublished data or correspondence with a trialist,
we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account risk of
bias for studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to our published protocol
and planned to justify any deviations from it in the Differences
between protocol and review section. There was no need to deviate
from the protocol (Slinger 2018).
Measures of treatment effect
We analysed dichotomous data as odds ratios (ORs) and con-
tinuous data as mean differences (MDs) or geometric MDs. We
planned that if data from rating scales were combined in a meta-
analysis, we would ensure that they were entered with a consistent
direction of effect (e.g. lower scores always indicate improvement).
The paucity of data meeting our inclusion criteria precluded fur-
ther consideration of this issue.
We planned to conduct meta-analyses only when meaningful, that
is when treatments, participants, and the underlying clinical ques-
tion were similar enough for pooling to make sense. Unfortunately,
there was no opportunity for aggregation.
We planned to describe skewed data narratively (e.g. as medians
and interquartile ranges for each group).
Had multiple trial arms been reported in a single study, we would
have included only the relevant arms. All of the trials meeting our
inclusion criteria were two-arm studies. In the protocol for this
review we stated that “If two comparisons (e.g. intervention A
vs usual care and intervention B vs usual care) are combined in
the same meta-analysis, we will either combine the active arms or
halve the control group to avoid double-counting”; however, this
was not an issue with the available data.
Where adjusted analyses were available (analysis of variance
(ANOVA) or analysis of covariance (ANCOVA)), we used these
as a preference in our meta-analyses. Where both change from
baseline and endpoint scores were available for continuous data,
we used change from baseline. We planned to avoid doing so in
the event of low correlation between measurements in individuals,
and there was no apparent indication of this issue. We planned
that where a study reported outcomes at multiple time points, we
would use change in baseline and endpoint scores.
When both per-protocol/completer and intention-to-treat (ITT)
analyses were provided in a single report, we used the latter.
Unit of analysis issues
For dichotomous outcomes, we used participants, rather than
events, as the unit of analysis (e.g. number of people experiencing
an adverse event, rather than number of adverse events per per-
son). However, we planned that if rate ratios had been reported in
a study, we would analyse them accordingly; this was not an issue
with the included studies. We planned to meta-analyse data from
cluster-RCTs only if available data had been adjusted (or could
be adjusted) to account for the clustering. Again, this was not an
issue with our included studies.
Dealing with missing data
We contacted the investigators of the included studies to verify
key study characteristics and for additional clarifications.
Assessment of heterogeneity
We planned to use the I² statistic to measure heterogeneity among
the studies in each analysis. Had we identified substantial hetero-
geneity, we would have reported this and explored possible causes
by performing prespecified subgroup analysis. However, there was
no opportunity for aggregation.
Assessment of reporting biases
We planned that if we had been able to pool more than 10 studies,
we would create and examine a funnel plot to explore possible
small-study and publication biases. However, there were insuffi-
cient studies meeting our inclusion criteria to pursue this aim.
Data synthesis
We used a random-effects model and planned to perform a sensi-
tivity analysis with a fixed-effect model if necessary.
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’Summary of findings’ table
We created a ’Summary of findings’ table using the following out-
comes.
Primary outcomes
1. Health-related quality of life (assessed with a validated
measure)
2. Serious adverse events
Secondary outcomes
1. Symptoms
2. Clinical improvement (as defined by trialists)
3. Subjective measures of cough (e.g. VAS/numerical cough
score)
4. Cough reflex sensitivity (as measured by cough challenge)
5. Objective cough counts
6. Adverse events/side effects
Reporting in the study of one or more of the outcomes listed here
was not an inclusion criterion for the review.
We used the five GRADE considerations (risk of bias, consistency
of effect, imprecision, indirectness, and publication bias) to assess
the quality of a body of evidence as it relates to studies that con-
tribute data for the prespecified outcomes. We used the methods
and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), employing GRADEpro software (GRADEpro
GDT). We justified all decisions to downgrade the quality of stud-
ies using footnotes, and included comments to aid the reader’s
understanding of the review when necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses on our
two primary outcomes (health-related quality of life and serious
adverse events). However, this was not possible due to the paucity
of data.
1. Number of sessions of SLT (one to three sessions versus
four to six sessions versus seven or more sessions).
2. Speech and language therapist-delivered intervention versus
intervention delivered by other healthcare professionals.
We planned to use the formal test for subgroup interactions in
Review Manager 5 (RevMan 2014).
Sensitivity analysis
We planned to conduct sensitivity analyses by removing studies
when the method of randomisation was judged as unclear or high
in the ’Risk of bias’ assessment. We also planned to conduct sen-
sitivity analyses by removing studies with an active control arm.
Furthermore, we planned to compare the results from a fixed-ef-
fect model with those from the random-effects model. However,
this was not possible due to the paucity of data.
R E S U L T S
Description of studies
Results of the search
We retrieved 141 references from the literature searches conducted
on 9 July 2018. We assessed 94 references after removal of duplicate
records (see study flow diagram in Figure 1).
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Figure 1. Study flow diagram.
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On 8 February 2019 we identified a further six references, with
no duplicates. In total we therefore assessed 100 references (see
Figure 1).
Included studies
We included two trials with a total of 162 randomised partici-
pants. One study was conducted across multiple sites in the UK
(Chamberlain Mitchell 2017), and another in Newcastle, Australia
(Vertigan 2006). Further clarification on the included studies was
requested and received from authors.
Populations
In Vertigan 2006, participants were eligible if cough was persis-
tent for more than two months following medical treatment in-
cluding treatment for asthma, postnasal drip syndrome, gastro-
oesophageal reflux, and withdrawal of angiotensin-converting en-
zyme inhibitors. The participants underwent thorough respiratory
history, hypertonic saline challenge, and induced sputum analysis
before inclusion in the study. The study included a total 87 par-
ticipants, randomised to placebo group (n = 44) and treatment
group (n = 43).
The eligibility criteria in Chamberlain Mitchell 2017 included
chronic cough (duration of more than two months) with nor-
mal chest x-ray, minimal sputum production, and negative and/
or failed treatments for asthma, gastro-oesophageal reflux disease,
and rhinitis. Patients were excluded if they had vocal cord nod-
ules, evidence of aspiration or malignancy. There were 75 eligi-
ble participants who were randomised to control group (n = 41)
and physiotherapy and speech and language therapy intervention
(PSALTI) group (n = 34).
Interventions
The intervention therapies used in the two included studies had
differing titles: Speech Pathology Evaluation and Intervention for
CHronic Cough (SPEICH-C) in Vertigan 2006 and PSALTI in
Chamberlain Mitchell 2017. However, the content was very sim-
ilar, comprising four one-to-one sessions of laryngeal hygiene and
hydration, cough suppression techniques, and psychoeducational
counselling around volitional control and the concept of the idio-
pathic nature of cough. Both studies used healthy lifestyle advice
as a control therapy with a focus on exercise, physical activity, diet
and nutritional advice, and stress management.
In one study, both the intervention and control therapies were
delivered purely by a speech and language therapist (Vertigan
2006). The other study delivered intervention therapy by either a
physiotherapist or speech and language therapist, and the control
therapy by a physiotherapist, speech and language therapist, or
nurse (Chamberlain Mitchell 2017).
The duration of treatment and length of sessions varied be-
tween studies, from four sessions delivered weekly in Chamberlain
Mitchell 2017 to four sessions over two months in Vertigan 2006.
Similarly, length of sessions varied slightly, from one 1-hour ses-
sion and three 45-minute sessions in Chamberlain Mitchell 2017
to four 30-minute sessions in Vertigan 2006.
Excluded studies
We excluded 90 records, with reasons given in the Characteristics
of excluded studies tables. A study flow diagram is shown in Figure
1. The primary reason for exclusion was: 59 (65%) were not rele-
vant to people with a diagnosis of UCC; 13 (14%) were reviews;
eight (9%) were not randomised studies; one (1%) did not include
an SLT intervention; one (1%) was an editorial; and one (1%) was
a comparison between pregabalin in addition to speech pathology
versus speech pathology alone. An additional trial considered the
benefit of adding video recordings of speech therapy techniques,
demonstrated by a speech pathologist, to support participants’ de-
velopment of the technique for chronic refractory cough (1%).
Risk of bias in included studies
A full ’Risk of bias’ assessment for each study can be found in the
Characteristics of included studies tables, and a summary of our
judgements in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
We assessed Chamberlain Mitchell 2017 and Vertigan 2006 as at
low risk of bias for random sequence generation and allocation
concealment.
Blinding
We judged Chamberlain Mitchell 2017 and Vertigan 2006 as
at unclear risk of performance bias. We assessed Chamberlain
Mitchell 2017 as at low risk and Vertigan 2006 as at unclear risk
of detection bias. Our judgments of unclear risk of bias reflect our
uncertainty in relation to reporting.
Incomplete outcome data
We assessed Chamberlain Mitchell 2017 and Vertigan 2006 as at
low risk of attrition bias.
Selective reporting
We judged Chamberlain Mitchell 2017 and Vertigan 2006 as at
unclear risk of reporting bias. As in the assessments of blinding,
our judgments of unclear risk of bias reflect our uncertainty in
relation to reporting, as we did not have access to trial protocols.
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Effects of interventions
See: Summary of findings for the main comparison Speech
and language therapy compared with healthy lifestyle advice for
chronic cough
Primary outcomes
Health-related quality of life (HRQoL)
Only one study contributed data to this outcome, and using the
GRADE approach we judged the quality of evidence to be low
(Summary of findings for the main comparison). Health-related
quality of life was assessed by Chamberlain Mitchell 2017 with the
Leicester Cough Questionnaire (LCQ). Data were analysed using
ANCOVA and reported as between-group difference from base-
line to four weeks (mean difference (MD) 1.53, 95% confidence
interval (CI) 0.21 to 2.85; participants = 71; studies = 1; Analysis
1.1), revealing a statistically significant benefit for PSALTI versus
control. This difference is also clinically significant as it exceeds
the minimum clinically important difference (MCID) of 1.3 in
chronic cough (Raj 2009). Our analysis focused on the 71 ITT
population participants (of the total 75 entering the study). This
statistically significant difference for PSALTI versus control was
not maintained between four weeks and three-month follow-up.
There were no differences between the two groups from baseline
to four weeks on general health and mood assessments, that is the
36-item Short Form Health Survey (SF-36) and Hospital Anxiety
and Depression Scale (HADS) scores.
We did not attempt subgroup analyses due to the paucity of the
data.
Serious adverse events
Vertigan 2006 did not report serious adverse events. Chamberlain
Mitchell 2017 reported that there were no serious adverse events
in either the PSALTI or control arms of the study (Analysis 1.2).
We judged the quality of the evidence to be low using the GRADE
approach (Summary of findings for the main comparison).
Secondary outcomes
Objective cough counts
Cough frequency per hour over a 24-hour period was measured
by Chamberlain Mitchell 2017. This was analysed as geometric
means, which compare the ratio of mean cough counts per hour
on treatment to control. The Leicester Cough Monitor (LCM)
is a validated, objective, semi-automated, and ambulatory cough-
monitoring device that was used in this study to assess objective
cough frequency (Birring 2008). The device was worn by partic-
ipants for 24 hours at baseline, at 4 weeks (after the fourth treat-
ment session), and at 3-month follow-up; in each of these sessions
the device recorded the number of coughs per hour. The effect
estimate favoured PSALTI (versus control), which was associated
with a ratio of cough counts per hour of 59% (95% CI 37% to
95%; participants = 71; studies = 1; Analysis 1.3) of cough counts
per hour on control. We judged the quality of this evidence to
be low using the GRADE approach (Summary of findings for
the main comparison). This statistically significant difference for
PSALTI versus control was not maintained between four weeks
and three-month follow-up.
Symptoms
Vertigan 2006 reported a significant benefit for the SLT interven-
tion (SPEICH-C) versus control for change in total symptoms
scores over the four treatment sessions (MD 9.80, 95% CI 4.50 to
15.10; participants = 87; studies = 1; Analysis 1.4). We are aware
that these data are skewed, and were analysed with non-parametric
methods by Vertigan 2006. In the non-parametric analysis there
was a significant difference between groups, favouring SPEICH-
C versus control. We judged the quality of the evidence to be low
using the GRADE approach (Summary of findings for the main
comparison).
Clinical improvement (as defined by trialists)
Vertigan 2006 demonstrated a significant improvement follow-
ing SPEICH-C versus control for change in symptoms scores of
breathing, cough, voice, upper airway, and limitation over the
four treatment sessions (odds ratio (OR) 48.13, 95% CI 13.53 to
171.25; participants = 87; studies = 1; Analysis 1.5). Each partici-
pant’s outcome was categorised by a speech and language therapist
as successful, unsuccessful, or partially successful. The assessment
was based on the participant’s informal reports of the effectiveness
of the intervention together with the speech and language ther-
apist’s clinical judgement of the participant’s understanding and
implementation of the intervention. Thirty-eight out 43 partici-
pants in the SPEICH-C group were regarded as having a successful
outcome in relation to these criteria, whereas only six out of 44
participants in the control group were judged to have a success-
ful outcome. Using the GRADE criteria, we judged the quality
of this evidence as very low (Summary of findings for the main
comparison).
Chamberlain Mitchell 2017 found no differences between groups
with respect to a vocal performance questionnaire from baseline
to four weeks.
Subjective measures of cough (e.g. visual analogue scale
(VAS)/numerical cough scale score)
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Only one study contributed data to this outcome, and we judged
the quality of the evidence as low using the GRADE approach
(Summary of findings for the main comparison). Cough sever-
ity, measured on a VAS (ranging from 0 to 100 mm, with higher
scores denoting higher severity) (Boulet 2015), was reported by
Chamberlain Mitchell 2017 (MD −9.72, 95% CI −20.80 to
1.36; participants = 71; studies = 1; Analysis 1.6). The mean dif-
ference favoured the intervention, but the result is uncertain as
the confidence interval includes the possibility of no difference be-
tween groups. Similarly, there was no difference for PSALTI versus
control between four weeks and three-month follow-up.
Cough reflex sensitivity (as measured by cough challenge)
There was no significant difference between PSALTI and control
in the capsaicin cough challenge for either the two or five cough
thresholds (capsaicin concentration to induce five coughs: 1.11
(95% CI 0.80 to 1.54) times higher on treatment than on con-
trol; participants = 49; studies = 1; Analysis 1.7) (Chamberlain
Mitchell 2017). We judged the quality of the evidence to be low
using the GRADE approach (Summary of findings for the main
comparison).
Adverse events/side effects
Adverse events were not reported by Vertigan 2006. Chamberlain
Mitchell 2017 reported no adverse events in either the PSALTI or
control conditions (Analysis 1.8). We judged the quality of this
evidence as low using the GRADE approach (Summary of findings
for the main comparison).
D I S C U S S I O N
Summary of main results
Overall there was a paucity of controlled trial data. We found only
two randomised trials that met our inclusion criteria (Chamberlain
Mitchell 2017; Vertigan 2006). Both were undertaken in adults
with UCC and examined the effect of an intervention versus
healthy lifestyle advice. Chamberlain Mitchell 2017 (conducted
in the UK) examined the effect of a physiotherapy and speech and
language therapy intervention (PSALTI) on HRQoL and mea-
sures of cough. Vertigan 2006 (conducted in Australia) studied the
effect of a speech therapy intervention (SPEICH-C) on symptom
scores.
There was a significant improvement in HRQoL (LCQ) scores at
four weeks, but not between four weeks and three months; how-
ever, these data were from one study only (Chamberlain Mitchell
2017), as this outcome was not included in Vertigan 2006. No
serious adverse events were reported, however information on this
outcome was not specifically stated in one of the trials (Vertigan
2006).
We found statistically significant improvements in 24-hour cough
frequency at four weeks when comparing PSALTI to control, but
this difference was not maintained between four weeks and three
months. The effect of PSALTI on subjective measures of cough was
uncertain with no statistically significant difference in cough sever-
ity measured on a VAS, although the mean difference favoured the
intervention. These data were from only one study (Chamberlain
Mitchell 2017).
We found statistically significant improvements in symptom scores
following the SLT intervention in Vertigan 2006..
Overall completeness and applicability of
evidence
Due to the absence of common outcomes in the two studies,
opportunities for statistical aggregation did not arise, and conse-
quently, whilst the results are encouraging, the paucity of evidence
precludes us from drawing robust conclusions to guide clinical
practice.
Only two studies with modest sample sizes met our inclusion cri-
teria. They were both conducted in high-income settings, there-
fore the global applicability of the evidence is limited. More-
over, the two studies used different outcomes, precluding di-
rect statistical aggregation. The interventions were based either
on SLT, Vertigan 2006, or SLT and physiotherapy combined
(Chamberlain Mitchell 2017). Both studies appeared to employ
similar treatment approaches, as first described by Vertigan 2006.
In Chamberlain Mitchell 2017, the Active Cycle of Breathing
Technique (ACBT) was introduced if the participant’s sputum
production was close to the limit of sputum exclusion criteria,
and nasal douche for nasal mucus hypersecretion. The benefit of
physiotherapy techniques in addition to SLT techniques was not
investigated in Chamberlain Mitchell 2017, hence it is not pos-
sible to draw conclusions on the relative positive contribution of
discipline-specific interventions (Smith 2017).
Quality of the evidence
The overall quality of the evidence presented in this review is
low for seven of the eight outcomes included in the GRADE as-
sessment; the quality of the evidence from the remaining out-
come ’clinical improvement (as defined by trialists)’ was judged
as very low when assessed by the GRADE criteria. However, only
two studies met our inclusion criteria. Both studies described
methods of randomisation, and these were similar. The control
and intervention arms for the two studies were comparable and
clearly defined, although one study had a two-month interven-
tion arm with no long-term outcome data (Vertigan 2006), and
the other study had a four-week intervention arm with four-week
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and three-month postintervention outcome data (Chamberlain
Mitchell 2017). One study used the treating speech therapist’s
judgement on clinical outcome and symptom scores (Vertigan
2006), whilst the other study used a validated questionnaire, in-
terval cough monitoring, and VAS to assess the effect of the inter-
vention (Chamberlain Mitchell 2017). The latter study also un-
dertook general health and mood assessments using the SF-36 and
HADS. The two studies also used different primary and secondary
endpoints. The variance in data collection and analysis meant it
was not possible to statistically combine the two studies for any
outcome. The quality of the evidence was limited critically by the
lack of studies meeting our inclusion criteria, and of those that
did meet our inclusion criteria, by the lack of consistency in data
collection methodology, duration of follow-up, and primary and
secondary endpoints analysed.
The two included studies by Vertigan 2006 and Chamberlain
Mitchell 2017 were single-blinded, and symptom ratings were
blinded. It was not possible to blind the treating therapist, and
there is inevitably the possibility of unconscious bias having been
conveyed to the participants; this is not a criticism of these well-
conducted studies, but a feature of the interventions, introducing
concomitant uncertainty in this regard.
In our GRADE assessment we deducted one point to reflect the
study question, which precluded the opportunity to double-blind,
and an additional point to reflect imprecision (data from a single
study with modest sample size); this was applied to all outcomes
considered in the Summary of findings for the main comparison.
We deducted a further point for the outcome ’clinical improve-
ment (as defined by trialists)’ to reflect that the judgement of ef-
ficacy on this outcome was made against criteria defined by the
trialists.
Potential biases in the review process
We recognise that there is the possibility of publication bias, which
could influence our understanding of the effects of the interven-
tions reported in this review. Studies demonstrating an absent or
negative effect of the proposed intervention are less likely to have
been presented or accepted for publication. Subsequently, data
that are made available for review could, as a result, be biased. Due
to the small number of trials included in the review, it was not pos-
sible to assess the significance of publication bias formally. How-
ever, potentially eligible studies were identified using a robust, sys-
tematic search process conducted by experienced specialists using
multiple sources including journals, conference publications, elec-
tronic databases, reference and citation lists of included studies,
and trial registries. It is possible that some studies may have been
inaccurately classified as not eligible for inclusion in the review.
Due to the small number of studies included, we did not perform
a sensitivity analysis to explore the impact of excluding studies that
did not meet agreed criteria. Any studies excluded from analysis
were done so on the basis of agreed and consistent criteria. There
is the potential for errors to occur in data entry for some full-text
reports; however, we took measures to double-check all data in an
attempt to avoid this during data extraction. All papers included
in the review process were independently assessed by two review
authors, with data corroborated by a third review author. Owing
to the variability in outcomes reported across the included stud-
ies, we were unable to statistically combine the overall findings.
However, we contacted the chief authors of the included studies,
and both were willing and able to provide further clarity on their
methodology and interpretation of data. We therefore feel that
we have taken thorough measures to minimise risk of bias in this
review, and are confident in the merit of outcomes individually
reported in the included studies.
Agreements and disagreements with other
studies or reviews
We are aware of reviews of chronic cough in the literature that
assess diagnosis and management, but they differ in primary ob-
jectives and methodologies used. Vertigan 2007 reviews behaviour
modification therapies in chronic cough using systematic reviews
and case studies to explain the main constructs required to deliver
effective non-pharmacological therapies to treat chronic cough.
The components of cough suppression therapy are further re-
viewed by Chamberlain 2013. Each of the four therapy compo-
nents are reviewed individually and the evidence base considered
to provide a structure for the speech and language therapist/res-
piratory physiotherapist to use to support patient outcome. Ryan
2014 reviewed the treatment of refractory chronic cough with
speech and language therapy and gabapentin via RCTs, system-
atic reviews, and case reports in English publications eight years
prior to their paper, concluding that behavioural treatment and
pharmacological neuromodulation have a role. Chronic cough can
arise due to known respiratory as well as non-respiratory pathol-
ogy. Molassiotis 2010 undertook a systematic review in adults in-
cluding RCTs and controlled trials to evaluate the effectiveness
of pharmacological and non-pharmacological interventions in the
relief of chronic cough excluding malignant disease. Guidelines for
the diagnosis and treatment of chronic cough were published in
Chest (Gibson 2016), using the best available evidence from RCTs
and systematic reviews. Eleven RCTs were included, but only one
looked at non-pharmacological intervention as the major compo-
nent of the study. The Chamberlain Mitchell 2017 RCT postdated
all these review articles, and its impact on UCC is not assessed. A
further review included all studies examining non-pharmacologi-
cal treatments in UCC focusing on potential mechanisms and the
effects of treatment (Chamberlain Mitchell 2019).
There is a paucity of evidence in this area with regard to outcomes
of speech and language therapy in the management of chronic
cough. The RCTs that do exist use similar methodologies of treat-
ment, but interstudy data analysis is not possible due to the ab-
sence of common outcome measures.
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It is important to note that Vertigan 2016, although not meeting
the inclusion criteria for this review, found that SLT, when com-
bined with the neuromodulator pregabalin, led to a significantly
greater improvement in participants’ perceived cough severity and
cough-related quality of life, when compared to SLT alone. This
combination of SLT and pregabalin was also found to improve
cough sensitivity. This benefit was sustained after treatment with-
drawal. However, due to observed adverse effects of pregabalin,
the authors state that this multimodal treatment should be re-
served for those with more severe end spectrum cough symptoms.
Further studies to help understand who may benefit from com-
bined pharmacological and non-pharmacological approaches, and
the timing of each component, may help inform clinical practice
further. This study is of clinical interest to professionals working
with people with UCC, although data from this single trial would
need to be confirmed in subsequent research to provide us with
robust evidence to guide clinical practice.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found only two trials meeting our inclusion criteria, which
included a combined total of 162 randomised adult participants.
Neither of the studies included children.
We identified positive effects in one study of speech and language
therapy (SLT)-based approaches, in combination with physiother-
apy, for our predefined primary outcome of health-related quality
of life (HRQoL). No adverse events were reported (Chamberlain
Mitchell 2017).
However, the between-group benefits of the intervention with re-
gard to HRQoL in Chamberlain Mitchell 2017 were found to be
short-lived, and this finding needs to be interpreted with caution
when applying it to clinical practice. Vertigan 2006 did not report
data on HRQoL.
Further high-quality studies with comparable endpoints are
needed to inform robust conclusions and guide clinical practice.
Implications for research
The paucity of data in this review highlights the need for more
randomised controlled trial data examining the efficacy of SLT in
the management of UCC. This review highlights that endpoints
vary between the included studies.
The improvements in HRQoL (Leicester Cough Questionnaire)
and reduction in 24-hour cough frequency seen with the physio-
therapy and speech and language therapy intervention (PSALTI)
were statistically significant but short-lived, with the effect lasting
up to 4 weeks only between PSALTI and control groups. Further
studies examining SLT intervention in UCC are required to repli-
cate these findings and to investigate the effects of the interven-
tions over time. It is clear that SLT interventions vary between
studies. Further research is needed to understand which aspects of
the SLT intervention are most effective in reducing cough (both
objective cough frequency and subjective measures of cough) and
improving HRQoL. We consider these endpoints to be impor-
tant clinically. It is also important for studies to report any adverse
events that occur. Further studies could be designed to understand
the essential components of the intervention (Smith 2017).
Further research is needed to investigate whether the results of this
review are applicable across cultures and along the age spectrum.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chamberlain Mitchell 2017
Methods Multicentre, single-blinded randomised controlled trial
Participants Treatment (PSALTI) group n = 34 (8 did not receive allocated intervention)
Control group n = 41 (4 did not receive allocated intervention)
• Age (median years and IQR): treatment (PSALTI) group 56 years (48 to 67 years)
; control group 61 years (53 to 67 years)
• Female, n (%): treatment (PSALTI) group 26 (63%); control group 25 (71%)
Trial report notes the groups were well matched at baseline, with the exception of SF-36
PCS (higher in the control group)
Inclusion criteria:
Reported as: adults with chronic cough (defined as duration > 2 months), with normal
chest X-ray, minimal sputum production (< 10 mL sputum a day) with negative investi-
gations and/or failed treatment trials for asthma, gastro-oesophageal reflux disease, and
rhinitis, as per British Thoracic Society guidelines
Exclusion criteria:
Reported as: patients were excluded if they had had an upper respiratory tract infection
in the past 4 weeks, were taking ACE inhibitors, were current smokers, or had a known
respiratory disease (such as lung cancer, pneumonia, pulmonary fibrosis, sarcoidosis,
pleural effusion, bronchiectasis). Patients were also excluded if they had vocal cord nod-
ules, malignancy, or evidence of active aspiration
Interventions PSALTI consisted of education, laryngeal hygiene and hydration, cough suppression
techniques, breathing exercises, and psychoeducational counselling. Participants at-
tended weekly sessions and received 1-to-1 treatment from a healthcare professional
(physiotherapist or speech and language therapist) over 4 weeks. Session durations were
the same as for the control group
Participants in the control group attended weekly sessions and received 1-to-1 standard-
ised healthy lifestyle advice from a healthcare professional (nurse, physiotherapist, or
speech and language therapist) over 4 weeks. The control intervention was based on that
used in the trial reported by Vertigan 2006. The initial session covered general advice
on exercise and physical activity; the second session dietary and nutritional advice; the
third session stress management; and the fourth session relaxation. The material covered
in each session was based on healthy lifestyle advised by the UK Department of Health
and National Health Service
Outcomes Primary outcome(s):
• Leicester Cough Questionnaire (LCQ) at week 4. Participants independently
completed questionnaires at baseline, at 4 weeks (after fourth treatment session), and at
3-month follow-up.
Secondary outcomes:
• Leicester Cough Monitor (LCM)
• Cough severity in the past 2 weeks was assessed by VAS (0 to 100 mm) as per
American College of Chest Physicians guideline
• The Vocal Performance Questionnaire (VPQ) (32), a 12-item tool used to assess
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patients’ perceived impact on their voice, since a high prevalence of voice disorders in
people with chronic cough has been reported
• SF-36
• Hospital Anxiety and Depression Scale (HADS)
Secondary endpoints were assessed at baseline, 4 weeks, and 3 months
Capsaicin cough challenge was assessed in a subset of the participants (King’s College
Hospital Foundation Trust and Northumbria Healthcare NHS Foundation Trust) to
measure participants’ cough reflex sensitivity at baseline and at 4 weeks (after fourth
treatment session)
Notes Study conducted across 3 hospitals in the UK (King’s College Hospital NHS Founda-
tion Trust, Lancashire Teaching Hospitals NHS Foundation Trust, and Northumbria
Healthcare NHS Foundation Trust). 2 further sites, Royal Brompton & Harefield NHS
Foundation Trust and Guy’s and St Thomas’ NHS Foundation Trust, were recruitment-
only sites, and participants were referred to King’s College Hospital to receive the inter-
vention. The study was undertaken between December 2011 and April 2014
Funded by: Chartered Society of Physiotherapy Charitable Trust, UK (Award PRF 10/
4). Additional funding was obtained from NIHR-CRN; King’s College Hospital NHS
Foundation Trust; London National Institute for Health Research (NIHR)/Wellcome
Trust; King’s Clinical Research Facility and the NIHR Biomedical Research Centre and
Dementia Unit at South London and Maudsley NHS Foundation Trust and King’s
College London; National Institute for Health Research Biomedical Research Centre
at Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust and King’s
College London; NIHR Collaboration for Leadership in Applied Health Research and
Care South London (CLAHRC South London)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Reported as: Participants were block-ran-
domised, stratified by age (above and be-
low 50 years old) and gender by the King’s
Clinical Trials Unit, King’s College London
Allocation concealment (selection bias) Low risk Reported as: Participants were registered
into the randomisation service provided by
the King’s Clinical Trials Unit, King’s Col-
lege London. This prevented foreknowl-
edge of treatment assignment for the study
researchers. Group allocation was con-
cealed from participants until they had
completed the study and all postinterven-
tion assessments
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reported as: The study was single-blinded.
It was not possible to blind the treating
therapist to the intervention the participant
received
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported as: Potential bias was minimised
by asking participants to complete their
primary outcome measures independently
from the treating therapist, and partici-
pants remained blinded until after comple-
tion of the final postintervention outcome
measures
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reported as: 75 participants were ran-
domised and had baseline assessments. 1
additional participant was randomised to
the PSALTI group but did not attend base-
line assessments. 4 participants did not re-
ceive any treatment (PSALTI group (n = 3)
: myocardial infarction prior to treatment,
unable to travel to hospital, and insufficient
time for the study; control group (n = 1)
: undisclosed illness prior to start of treat-
ment)
Selective reporting (reporting bias) Unclear risk No apparent indication of selective report-
ing, but we did not have access to trial pro-
tocols
Vertigan 2006
Methods Single-blinded randomised controlled trial
Participants Treatment (SPEICH-C) group n = 43
Control group n = 44
• Age (mean years and SD): treatment (SPEICH-C) group 57.5 years (13.8);
control group 61.3 years (13.2)
• Female, n (%): treatment (SPEICH-C) group 35 (81%); control group 29 (66%)
Trial report notes the groups were well balanced with respect to age, sex, reflux, ACE
inhibitor use, allergies, asthma, postnasal drip syndrome, and smoking status
Inclusion criteria:
Reported as: chronic cough was defined as the presence of chronic coughing that persisted
for 2 months following medical treatment based on the approach recommended by Irwin
1998. The severity of the cough was sufficient for patients to seek medical attention from
both general practitioner and respiratory physician. Patients had undergone respiratory
case history, hypertonic saline challenge, and induced sputum analysis before inclusion
in the study. Significant symptoms identified during the case history were subsequently
investigated and treated. A minimum age of 18 years and ability to travel to John Hunter
Hospital
Exclusion criteria:
Reported as: recent upper respiratory tract infection, untreated allergy, PNDS, asthma,
GER, eosinophilic bronchitis, lung pathology, abnormality on the chest radiograph,
COPD, and neurological voice disorder
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Interventions In the intervention group, participants received Speech Pathology Evaluation and Inter-
vention for CHronic Cough (SPEICH-C). The SPEICH-C comprises 4 components
including education about the nature of chronic cough, strategies to control the cough,
psychoeducational counselling, and vocal hygiene education to reduce laryngeal irrita-
tion. These techniques were designed to improve the efficiency of voicing by reducing
the load on the larynx while promoting adequate breath support and oral resonance.
The education component emphasised the futility and negative side effects of repeated
coughing, the benefits of cough suppression, and the capacity of individuals to develop
voluntary control over cough. The cough suppression component required participants
to anticipate when a cough was about to occur and then implement a strategy to suppress
or replace the cough. The vocal hygiene component included strategies to reduce laryn-
geal irritation and maximise hydration in order to reduce stimulation of cough receptors.
Relaxed throat breathing exercises were also provided for those participants with inspi-
ratory dyspnoea. The psychological component was designed to facilitate internalisation
of control over their cough and view the cough as something individuals do in response
to irritating stimuli rather than a phenomenon outside the participant’s control
In the control group, participants received an equivalent course of healthy lifestyle edu-
cation
Participants in both groups attended 4 individual 30-minute intervention sessions sched-
uled over a 2-month period
Outcomes Outcomes:
• Symptom scores (including components for cough, breathing, voice, upper
airway, and limitation)
• The clinical outcome for each participant was rated as successful, unsuccessful, or
partially successful
A division between primary and secondary outcomes was not explicitly made in the trial
report
Notes Study conducted at the John Hunter Hospital, New South Wales, Australia between
April 2003 and October 2004
Funded by: The Hunter Medical Research Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study randomised by random number gen-
eration.
Allocation concealment (selection bias) Low risk Reported as: The treating speech pathol-
ogist was not involved in the randomisa-
tion process; however, once the treatment
group was allocated, the speech patholo-
gist knew the participant’s group allocation.
Group allocation was concealed from par-
ticipants until the postintervention symp-
tom rating and clinical judgement of out-
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come had been recorded
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reported as: Because of the single-blinded
design of this study and the nature of the
intervention programmes, it was not possi-
ble to blind the treating speech pathologist
to the type of intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reported as: 1 participant in the treat-
ment group and 4 in the placebo group
did not commence their respective in-
tervention programmes because of unex-
pected family responsibilities and sponta-
neous resolution of symptoms before treat-
ment commenced. 3 participants in the
treatment group and 2 in the placebo group
discontinued intervention through failure
to contact or attend appointments
Selective reporting (reporting bias) Unclear risk No apparent indication of selective report-
ing, but we did not have access to trial pro-
tocols
ACE: angiotensin-converting-enzyme; COPD: chronic obstructive pulmonary disease; GER: gastro-oesophageal reflux; IQR: interquar-
tile range; PNDS: postnasal drip syndrome; PSALTI: physiotherapy and speech and language therapy intervention; SD: standard
deviation; SF-36 PCS: the SF-36 is a generic (rather than disease-specific) 36-item, patient-reported health-related quality of life
scale; ’PCS’ refers to the physical component score from the instrument (and excludes data from the mental component score); VAS:
visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ackerstaff 1995 Not cough patients. No speech and language therapy intervention (comparison: heat and moisture exchangers
intervention and no placebo)
Al-Riyami 2001 Cross-sectional study using a questionnaire. Non-randomised study. Non-interventional. Participants do not
have a diagnosis of chronic unexplained (idiopathic/refractory) cough
Bemanin 2015 Cross-sectional questionnaire study. Not a randomised trial. Participants do not have a diagnosis of chronic
unexplained (idiopathic/refractory) cough
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Benninger 2011 Review. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough
Birring 2017 Review
Biswas 2015 Retrospective (non-randomised) study. Participants do not have a diagnosis of chronic unexplained (idiopathic/
refractory) cough
Brady 2018 Non-randomised study. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory)
cough
Cacciari 2017 Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough. Interventions do not
include speech and language therapy techniques (non-interventional study)
Carmel 2016 Literature review. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough
and no speech and language therapy intervention
Chamberlain 2013 Review
Cholera 2016 Review. Does not relate to a diagnosis of chronic unexplained (idiopathic/refractory) cough
Dart 2003 Review. Does not relate to a diagnosis of chronic unexplained (idiopathic/refractory) cough
Faria 2014 Retrospective case control study. Participants do not have a diagnosis of chronic unexplained (idiopathic/
refractory) cough. No speech and language therapy intervention and no randomisation
Fernandez 2015 Non-randomised study. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory)
cough




Goldstein 2007 Case report. Not a randomised trial
Good 2018 Not a randomised controlled trial
Harvey 2018 Participant did not have a diagnosis of chronic cough. Single case report. Not a randomised trial
Hertegard 2002 Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough. No speech and
language therapy intervention for chronic unexplained (idiopathic/refractory) cough (comparison: hylan B gel
with no placebo arm)
Hilgers 1996 Not a randomised study. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory)
cough
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Hilgers 2003 Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough. No speech and
language therapy (comparison: reusable, multi-magnet automatic speaking valve with no placebo arm)
Hull 2005 Retrospective case review not relating to chronic unexplained (idiopathic/refractory) cough
Hunter 2011 Non-randomised study. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory)
cough
Ihalainen 2015 Non-randomised study. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory)
cough
Irons 2010 Systematic review. Does not relate to participants with a diagnosis of chronic unexplained (idiopathic/refractory)
cough
Irwin 2010 Review. Not a randomised trial
Jensen 2013 Non-randomised study. No intervention. Not in participants with a diagnosis of chronic unexplained (idio-
pathic/refractory) cough
Kapela 2019 Participants were randomised to receive either a standard speech pathology intervention or standard speech
pathology intervention + supplemental pre-recorded videos to support practice at home. The comparison was
therefore not speech pathology intervention versus no intervention to evaluate the effectiveness of speech and
language therapy for treatment of chronic cough
Kew 2017 Systematic review. Non-randomised trial. Not in participants with a diagnosis of chronic unexplained (idio-
pathic/refractory) cough
Killoran 2012 Review
Kyriakou 2018 Participants did not have a diagnosis of chronic cough, and the study was not a randomised controlled trial
Lukrafka 2010 Cross-sectional study. Not a randomised trial. Participants do not have a diagnosis of chronic unexplained
(idiopathic/refractory) cough
Marques 2015 Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough. Interventions do not
include speech and language therapy techniques. Intervention is pelvic floor/hip strengthening
McGarvey 2013 Review. Not specifically examining intervention of speech and language therapy in participants with a diagnosis
of chronic unexplained (idiopathic/refractory) cough
Mellor 1998 Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough. No speech and
language therapy intervention (comparison: bupivacaine versus ketorolac)
Mesia 2010 Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough. No speech and
language therapy intervention (comparison: cetuximab platinum-fluorouracil versus platinum-fluorouracil)
Michaudet 2017 Review
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(Continued)
Molassiotis 2010 Systematic review. Non-randomised. Not specifically examining effect of speech and language therapy in chronic
unexplained (idiopathic/refractory) cough
Morice 2017 Review. Focus is not on a diagnosis of chronic unexplained (idiopathic/refractory) cough in patients who have
undergone a full diagnostic workup to exclude an underlying cause, as per published guidelines or local protocols
NCT03457610 Not a randomised trial
Oner 2013 Not a randomised trial
Oskam 2013 Non-randomised trial. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough
Park 2017 Not a randomised study. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory)
cough
Patterson 2007 Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough. No speech and
language therapy intervention (comparison: miglustat versus usual care)
Perez 2011 Non-randomised study. Not in participants with a diagnosis of chronic unexplained (idiopathic/refractory)
cough
Perez 2012 Non-randomised study. Not in participants with a diagnosis of chronic unexplained (idiopathic/refractory)
cough
Plowman 2016 Not in participants with a diagnosis of chronic unexplained (idiopathic/refractory) cough who have undergone
a full diagnostic workup to exclude an underlying cause, as per published guidelines or local protocols. Inter-
ventions do not include speech and language therapy techniques (intervention is inspiratory-expiratory exercise
in amyotrophic lateral sclerosis)
Pohl 2012 Review. Focus not on a diagnosis of chronic unexplained (idiopathic/refractory) cough. No speech and language
therapy intervention
Raggi 2016 Non-randomised study. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory)
cough. Speech and language therapy intervention is on swallow rather than cough
Reverberi 2019 Participant did not have a diagnosis of chronic cough. Single case report. Not a randomised trial
Ryan 2009 Non-randomised study. No intervention. Participants do not have a diagnosis of chronic unexplained (idio-
pathic/refractory) cough
Ryan 2010 Study not randomised
Ryan 2014 Review
Ryan 2016 Retrospective review of effect of amitriptyline on chronic unexplained (idiopathic/refractory) cough. No speech
and language therapy intervention. Not a randomised trial
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Sauni 2013 Systematic review. Does not include participants with chronic unexplained (idiopathic/refractory) cough. No
speech and language therapy intervention
Selby 2017 Non-randomised study
Shem 2012 Cross-sectional study. Not a randomised trial. Participants do not have a diagnosis of chronic unexplained
(idiopathic/refractory) cough
Sitoh 2000 Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough
Smithard 1998 Not a randomised trial. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory)
cough
Soria 2013 Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough. Interventions do not
include speech and language therapy techniques (interventions were aimed at dysphagia)
Soria 2013a Non-randomised study. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory)
cough
Suiter 2014 Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough
Tong 2016 Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough. Interventions do not
include speech and language therapy techniques (comparison: Impact of expiratory muscle strength training
versus sham)
Vertigan 2007 Review
Vertigan 2011 Study not randomised
Vertigan 2012 Review. Not a randomised trial
Vertigan 2014 Non-randomised study. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory)
cough
Vertigan 2016 Trial compares pregabalin in addition to speech pathology versus speech pathology alone and therefore does
not meet our inclusion criteria
Vertigan 2018 Cross-sectional non-randomised study
Videnovic 2013 Non-randomised study. Review in Huntington’s disease (not chronic unexplained (idiopathic/refractory) cough)
. No speech and language therapy intervention
Weinberger 2010 Review. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough
Weinhardt 2008 Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough. Interventions do not
include speech and language therapy techniques; no specific interventions; examines agreement between nurses
and speech and language therapists in swallow assessments
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Wright 2012 Not a randomised study. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory)
cough
Wu 2017 Case report. Not a randomised trial. Participants do not have a diagnosis of chronic unexplained (idiopathic/
refractory) cough
Young 2008 Case report. Not a randomised trial. Participants do not have a diagnosis of chronic unexplained (idiopathic/
refractory) cough
Zhu 2013 Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory) cough
Zimmels 2015 Not a randomised trial. Participants do not have a diagnosis of chronic unexplained (idiopathic/refractory)
cough
Zobeiri 2011 Cross-sectional questionnaire study. Not a randomised trial
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D A T A A N D A N A L Y S E S
Comparison 1. Speech and language therapy versus healthy lifestyle advice




participants Statistical method Effect size
1 Health-related quality of
life (Leicester Cough
Questionnaire)
1 Mean Difference (Fixed, 95% CI) Subtotals only
2 Serious adverse events 1 75 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Objective cough counts (e.g.
using the Leicester Cough
Monitor)
1 Geometric Mean (Fixed, 95% CI) Subtotals only
4 Symptoms 1 Mean Difference (IV, Random, 95% CI) Totals not selected
5 Clinical improvement (as
defined by trialists)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
6 Subjective measures of
cough (e.g. visual analogue
scale/numerical cough scale
score)
1 Mean Difference (Fixed, 95% CI) Subtotals only
7 Capsaicin cough challenge (to
induce 5 coughs)
1 Geometric Mean (Fixed, 95% CI) Subtotals only
8 Adverse events/side effects 1 75 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Speech and language therapy versus healthy lifestyle advice, Outcome 1 Health-
related quality of life (Leicester Cough Questionnaire).
Review: Speech and language therapy for management of chronic cough
Comparison: 1 Speech and language therapy versus healthy lifestyle advice












N N IV,Fixed,95% CI IV,Fixed,95% CI
Chamberlain Mitchell 2017 31 40 1.53 (0.6735) 1.53 [ 0.21, 2.85 ]
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours control Favours SLT
38Speech and language therapy for management of chronic cough (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Speech and language therapy versus healthy lifestyle advice, Outcome 2 Serious
adverse events.
Review: Speech and language therapy for management of chronic cough
Comparison: 1 Speech and language therapy versus healthy lifestyle advice







advice Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chamberlain Mitchell 2017 0/34 0/41 Not estimable
Total (95% CI) 34 41 Not estimable
Total events: 0 (Speech % language therapy), 0 (Healthy lifestyle advice)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SLT Favours control
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Analysis 1.3. Comparison 1 Speech and language therapy versus healthy lifestyle advice, Outcome 3
Objective cough counts (e.g. using the Leicester Cough Monitor).
Review: Speech and language therapy for management of chronic cough
Comparison: 1 Speech and language therapy versus healthy lifestyle advice









(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Chamberlain Mitchell 2017 -0.5276 (0.243) 0.59 [ 0.37, 0.95 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SLT Favours control
Analysis 1.4. Comparison 1 Speech and language therapy versus healthy lifestyle advice, Outcome 4
Symptoms.
Review: Speech and language therapy for management of chronic cough













N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Vertigan 2006 43 12.7 (12.7) 44 2.9 (12.5) 9.80 [ 4.50, 15.10 ]
-100 -50 0 50 100
Favours control Favours SLT
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Analysis 1.5. Comparison 1 Speech and language therapy versus healthy lifestyle advice, Outcome 5 Clinical
improvement (as defined by trialists).
Review: Speech and language therapy for management of chronic cough
Comparison: 1 Speech and language therapy versus healthy lifestyle advice















Vertigan 2006 38/43 6/44 48.13 [ 13.53, 171.25 ]
0.005 0.1 1 10 200
Favours control Favours SLT
Analysis 1.6. Comparison 1 Speech and language therapy versus healthy lifestyle advice, Outcome 6
Subjective measures of cough (e.g. visual analogue scale/numerical cough scale score).
Review: Speech and language therapy for management of chronic cough
Comparison: 1 Speech and language therapy versus healthy lifestyle advice












N N IV,Fixed,95% CI IV,Fixed,95% CI
Chamberlain Mitchell 2017 31 40 -9.72 (5.6532) -9.72 [ -20.80, 1.36 ]
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours SLT Favours control
41Speech and language therapy for management of chronic cough (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 Speech and language therapy versus healthy lifestyle advice, Outcome 7
Capsaicin cough challenge (to induce 5 coughs).
Review: Speech and language therapy for management of chronic cough
Comparison: 1 Speech and language therapy versus healthy lifestyle advice















N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Chamberlain Mitchell 2017 22 27 0.1044 (0.1671) 1.11 [ 0.80, 1.54 ]
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours control Favours SLT
Analysis 1.8. Comparison 1 Speech and language therapy versus healthy lifestyle advice, Outcome 8
Adverse events/side effects.
Review: Speech and language therapy for management of chronic cough
Comparison: 1 Speech and language therapy versus healthy lifestyle advice







advice Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chamberlain Mitchell 2017 0/34 0/41 Not estimable
Total (95% CI) 34 41 Not estimable
Total events: 0 (Speech % language therapy), 0 (Healthy lifestyle advice)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SLT Favours control
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A P P E N D I C E S
Appendix 1. Database search strategies
CENTRAL (Cochrane Register of Studies)
#1 MESH DESCRIPTOR Cough EXPLODE ALL
#2 cough*:ti,ab,kw
#3 #2 OR #1
#4 MESH DESCRIPTOR Rehabilitation of Speech and Language Disorders EXPLODE ALL
#5 ((speech* or language*) NEAR5 (therap* or treatment* or interven* or program* or train* or exercise* or rehabilit*))
#6 SLT:ti,ab
#7 #4 OR #5 OR #6
#8 #7 AND #3
Cochrane Airways Register of Trials (Cochrane Register of Studies)
#1 MESH DESCRIPTOR Cough EXPLODE ALL
#2 cough*:ti,ab,kw
#3 #2 OR #1
#4 MESH DESCRIPTOR Rehabilitation of Speech and Language Disorders EXPLODE ALL
#5 ((speech* or language*) NEAR5 (therap* or treatment* or interven* or program* or train* or exercise* or rehabilit*))
#6 SLT:ti,ab
#7 #4 OR #5 OR #6




3. 1 or 2
4. exp “rehabilitation of speech and language disorders”/
5. ((speech$ or language$) adj5 (therap$ or treatment$ or interven$ or program$ or train$ or exercise$ or rehabilit$)).tw.
6. SLT.ti,ab.
7. or/4-6
8. 3 and 7
9. (controlled clinical trial or randomized controlled trial).pt.









19. 17 not (17 and 18)
20. 16 not 19
21. 8 and 20
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3. 1 or 2
4. exp “speech and language rehabilitation”/
5. ((speech$ or language$) adj5 (therap$ or treatment$ or interven$ or program$ or train$ or exercise$ or rehabilit$)).tw.
6. SLT.ti,ab.
7. or/4-6
8. 3 and 7
9. Randomized Controlled Trial/
10. randomization/
11. controlled clinical trial/
12. Double Blind Procedure/
13. Single Blind Procedure/
14. Crossover Procedure/
15. (clinica$ adj3 trial$).tw.




20. ((control$ or prospectiv$) adj3 (trial$ or method$ or stud$)).tw.
21. (crossover$ or cross-over$).ti,ab.
22. or/9-21
23. exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
24. human/ or normal human/ or human cell/
25. 23 and 24
26. 23 not 25
27. 22 not 26




S3 S1 OR S2
S4 (MH “Rehabilitation, Speech and Language+”)
S5 ((speech* OR language*) n5 (therap* OR treatment* OR interven* OR program* OR train* OR exercise* OR rehabilit*))
S6 SLT
S7 S4 OR S5 OR S6
S8 S3 AND S7
S9 (MH “Clinical Trials+”)
S10 randomized or randomised
S11 placebo*
S12 randomly
S13 clinical* n3 (trial* or study or studies)
S14 (single* or double* or triple*) n3 blind*
S15 S9 OR S10 OR S11 OR S12 OR S13 OR S14
S16 S8 AND S15
ClinicalTrials.gov
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Search field Search terms
condition cough
intervention speech or language
Study type interventional
WHO ICTRP
Search field Search terms
condition Cough
Intervention Speech OR language
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